Clinical Trials · NCT02016911
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 56
- Start date
- Dec 2013
- Locations
- 6 sites, 3 countries
- Primary endpoint
- Area under the semaglutide plasma concentration curve